2020
DOI: 10.1111/dth.14200
View full text
|
Sign up to set email alerts
|
Share

Abstract: remained stable. To date, the patient continues 200 mg/daily sonidegib treatment in order to complete the 6-months treatment period. Sonidegib is a novel molecule that acts by inhibiting smoothened (SMO) protein, thus blocking the hedgehog pathway and tumor cells transcriprion. It was approved in July 2015 by the Food and Drugs Administration (FDA) and is available in 200 mg capsules for patients aged >18 years with laBCC who present recurrence to other treatments or who are not candidates for surgery or radio…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
2
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals